Source - LSE Non-Regulatory
RNS Number : 1726P
e-Therapeutics plc
16 February 2021
 

e-therapeutics PLC

 

e-therapeutics to present at Shares Investor Evening

 

 

Oxford, UK, 16 February 2021 - e-therapeutics plc (AIM: ETX.L, "e-therapeutics" or "the Company") will be presenting at the Shares Investor Evening - Webinar sponsored by AJ Bell on Wednesday 17th February 2021. The webinar will start at 18:00 BST and investors can register to attend here https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-170221

 

Ali Mortazavi, Chairman & CEO of e-therapeutics, will be presenting an overview of the Company and will be available to take questions during the event.

 

-Ends-

 

For further information, please contact:

 

e-therapeutics plc

Ali Mortazavi, Chairman & CEO Tel: +44 (0)1993 883 125

www.etherapeutics.co.uk

 

Numis Securities Limited

Freddie Barnfield/Duncan Monteith (Nominated Adviser)

James Black (Corporate Broking)

Tel: +44 (0) 207 260 1000

www.numis.com

 

About e-therapeutics plc

 

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

 

e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

 

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUVOBRAWUUAAR
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.